Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), commonly known as Long COVID, is a term used for patients that have recovered from acute COVID but have persistent symptoms lasting weeks or months. The number of people impacted by long COVID continues to increase as physicians are beginning to understand how to identify these patients and develop a multi-disciplinary treatment plan to address the various symptoms. In pursuit of answers, Labcorp is pleased to announce a webinar series devoted to the next pandemic, long COVID. In this series, the speakers will explore different topics specific to Long COVID that are impacting patients, physicians, as well as drug development companies.
In the first of our series, we explore the dizzying world of Postural Orthostatic Tachycardia Syndrome (POTS). POTS has traditionally been a highly symptomatic, potentially debilitating, often poorly understood medical condition and is notoriously a challenge to treat. The diagnosis of POTS itself can be difficult to make given the overlapping nature of the condition with other medical problems as well as discrepancies in the diagnostic criteria in published literature as well as amongst expert opinion. Now, as a result of the COVID pandemic, a new light has been shone on POTS as the population of patients diagnosed with the condition continues to rise.
Join this webinar to hear from two key opinion leaders in the field as we explore symptoms, diagnosis and potential mechanisms for post-COVID POTS as well as consider a framework for therapy.
Oren Cohen, MD, Head of Clinical Pharmacology Services and Chief Medical Officer, Labcorp Drug Development
Oren Cohen, MD, joined Labcorp Drug Development in December 2017 to serve as head of Clinical Pharmacology Services and Chief Medical Officer (CMO). Oren has extensive clinical development experience, most recently from Viamet Pharmaceuticals where he was CMO. He brings more than 30 years of healthcare experience to the role, including several senior medical and operational leadership positions at IQVIA, including Chief Medical and Scientific Officer and global head of Early Clinical Development.
Oren received his MD from Duke University and served his internship and residency at The New York Hospital, Cornell Medical Center in New York City. He completed his infectious diseases fellowship at the National Institute of Allergy and Infectious Diseases (NIAID) and stayed on to become an investigator in the Laboratory of Immunoregulation where he conducted basic and translational research on the immunopathogenesis of HIV infection under the supervision of Dr. Anthony Fauci. He served on the national antiretroviral guidelines panel and ultimately served as Assistant Director for Medical Affairs for NIAID.
Oren has published scientific papers in Science, The New England Journal of Medicine, The Lancet, The Journal of Clinical Investigation and Proceedings of the National Academy of Sciences, among others. He is a Fellow of the Infectious Diseases Society of America and a Consulting Professor of Medicine at Duke University Medical Center.Message Presenter
Artur Fedorowski, MD, PhD, Senior Consultant and Head of Syncope Unit, Dept. of Cardiology, Karolinska University Hospital
Dr. Artur Fedorowski earned his MD and PhD degrees from Wrocław Medical University, Poland, followed by specialist training in Sweden in general medicine, internal medicine and cardiology. He serves as a Senior Consultant and Head of Syncope Unit, Dept. of Cardiology at Karolinska University Hospital, and holds an academic position as an Associate Professor in the Department of Clinical Sciences at Lund University, both in Sweden. His research areas include syncope, orthostatic hypotension, cardiac arrhythmias, cardiovascular autonomic dysfunction, hypertension, biomarkers, autoimmune cardiovascular diseases and genetics of cardiovascular disease.
Dr. Fedorowski is a member of the Task Force Group of European Society of Cardiology for Syncope Guidelines and of the National Institutes of Health (U.S.) Expert Group on Postural Orthostatic Tachycardia Syndrome. He has authored more than 135 peer-reviewed publications and contributed to five books. He has also served as a guest editor for Frontiers in Cardiovascular Medicine and as a reviewer for more than 60 medical journals.Message Presenter
Brian Olshansky, MD, Professor Emeritus, University of Iowa; Adjunct Professor, Des Moines University; Clinical Cardiac Electrophysiologist
Brian Olshansky, MD, FACC, FAHA, FHRS, FESC, a board-certified, internationally known, clinical cardiac electrophysiologist graduated from Carleton College and University of Arizona School of Medicine, undertook his residency at Bellevue/NYU Hospitals and cardiology fellowship at the University of Iowa followed by electrophysiology training at the University of Alabama at Birmingham. He directed two cardiac electrophysiology programs – Loyola University Medical Center in Maywood, Illinois and the University of Iowa Hospitals and Clinics in Iowa City. He is Professor Emeritus at the University of Iowa, Adjunct Professor at Des Moines University and a cardiac electrophysiologist in practice in Iowa and Illinois.
Dr. Olshansky is known for his diversity of interests ranging from the technological and mechanistic aspects of cardiac electrophysiology to the holistic issues regarding medical care and the doctor-patient relationship. He has educated numerous cardiology and cardiac electrophysiology fellows, many of whom have gone onto brilliant careers.Message Presenter
Who Should Attend?
- Chief Medical Officer
- Senior Medical Director
- Medical Director
- Head of Clinical Development
- Clinical Development Director
- Research and Development Director
- Operational Director
- Senior Operational Director
- Clinical Director
- Senior Clinical Director
- Research Director
What You Will Learn
The goals of this presentation will be:
- To acquire a high-level understanding of Post-Acute Sequelae of SARS-CoV-2 (PASC)
- To discuss the symptoms, diagnosis and potential mechanisms of Post-COVID POTS
- To provide a framework for potential therapies to treat patients with Post-COVID POTS
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.